ImmuCell Corporation (ICCC) Earnings History
Annual and quarterly earnings data from 1989 to 2024
Loading earnings history...
ICCC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ICCC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 30.0% | -6.2% | -8.1% |
| 2023 | 25.2% | -32.9% | -33.1% |
| 2022 | 41.2% | -12.4% | -13.4% |
| 2021 | 45.0% | 1.3% | -0.4% |
| 2020 | 44.7% | -9.0% | -6.7% |
Download Data
Export ICCC earnings history in CSV or JSON format
Free sign-in required to download data
ImmuCell Corporation (ICCC) Earnings Overview
As of May 8, 2026, ImmuCell Corporation (ICCC) reported trailing twelve-month net income of $2M, reflecting +65.3% year-over-year growth. The company earned $0.26 per diluted share over the past four quarters, with a net profit margin of -8.1%.
Looking at the long-term picture, ICCC's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2000.
ImmuCell Corporation maintains positive profitability with a gross margin of 30.0%, operating margin of -6.2%, and net margin of -8.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including PCRX ($9M net income, 1.0% margin), NEOG (-$603M net income, -122.1% margin), PAHC ($92M net income, 3.7% margin), ICCC has room to improve margins relative to the peer group. Compare ICCC vs PCRX →
ICCC Earnings vs Peers
Earnings metrics vs comparable public companies
ICCC Historical Earnings Data (1989–2024)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$2M | +62.7% | -$2M | $-0.26 | -8.1% | -6.2% |
| 2023 | -$6M | -131.5% | -$6M | $-0.75 | -33.1% | -32.9% |
| 2022 | -$2M | -3085.5% | -$2M | $-0.32 | -13.4% | -12.4% |
| 2021 | $-78,292 | +92.3% | $257,385 | $-0.01 | -0.4% | 1.3% |
| 2020 | -$1M | +21.1% | -$1M | $-0.14 | -6.7% | -9.0% |
| 2019 | -$1M | +44.2% | $-954,000 | $-0.19 | -9.4% | -7.0% |
| 2018 | -$2M | -1282.1% | -$1M | $-0.42 | -21.1% | -13.2% |
| 2017 | $-168,000 | -133.0% | $-243,000 | $-0.03 | -1.6% | -2.3% |
| 2016 | $508,448 | -58.1% | $890,204 | $0.12 | 5.3% | 9.3% |
| 2015 | $1M | +825.8% | $2M | $0.38 | 11.9% | 20.7% |
See ICCC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ICCC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ICCC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonICCC — Frequently Asked Questions
Quick answers to the most common questions about buying ICCC stock.
Is ICCC growing earnings?
ICCC EPS is $0.26, with earnings growth accelerating to +65.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $2M.
What are ICCC's profit margins?
ImmuCell Corporation net margin is -8.1%, with operating margin at -6.2%. Below-average margins reflect competitive or cost pressures.
How consistent are ICCC's earnings?
ICCC earnings data spans 1989-2024. The accelerating earnings trend is +65.3% YoY. Historical data enables comparison across business cycles.